European Commission Approves FYB201/Ranivisio®(1) (Ranivisio - Ranibizumab), a Biosimilar to Lucenti

AMSTERDAM, the Netherlands, MUNICH, Germany and ZUG, Switzerland, August 29, 2022 / B3C newswire / -- Polpharma Biologics Group BV (“Polpharma Biologics”), Formycon AG (“Formycon”) and Bioeq AG (“Bioeq”) jointly announce that the European Commission (“EC”) has granted marketing authorization (“MA”) to Ranivisio® (Ra...

Related Keywords

Liechtenstein ,Germany ,Norway ,Australia ,Iceland ,Japan ,Munich ,Bayern ,Netherlands ,United Kingdom ,Canada ,Switzerland ,Amsterdam ,Noord Holland ,British ,Swiss ,Michael Soldan ,Polpharma Biologics ,Choroidal Neovascularization ,Ruder Finn ,Leah Peyton ,Stefan Glombitza ,Polpharma Biologics Group Bv ,European Commission ,Genentech Inc ,Regulatory Agency ,Teva Pharmaceutical Industries Ltd ,Polpharma Biologics Group ,European Union ,Biosimilar Pharmaceuticals ,European Medicines Agency ,Committee For Medicinal Products Human Use ,Medicinal Products ,Human Use ,Joint Venture ,Teva Pharmaceutical Industries ,Pharmaceutical Industries ,Securities Litigation Reform Act ,Product Characteristics ,United Kingdom Summary ,British Journal ,Macular Edema ,Retinal Vein Occlusion ,Diabetic Retinopathy ,Wet Macular Degeneration ,Vascular Endothelial Growth Factor ,Diabetes Mellitus ,Vision Disorders ,